1

Aventis Pharma

2

Aventis Pharma

Aventis Pharma

Prescription drugsAventis Pharma

VaccinesAventis Pasteur

Therapeutic proteinsAventis Behring

DiagnosticsDade Behring

3

Key Figures

•92, 500 employees – 80% in Pharma•16 Bn€ Pharma sales – 5th in top 10•Strong & growing US presence with >35% sales•19,000 member sales force •16.8% R&D expenditure; 6500 scientists &

technicians worldwide•15% of R&D expenditure dedicated to alliances;

about 50 major biotech collaborations; about 250 academic collaborations

4

Drug Innovation & Approval (R&D)Disease Groups supported by powerful technology

platforms

Gene Therapy*

-CV- Metabolic Diseases, - Osteoarthritis, Thrombosis

US

FRANCEGERMANY

JAPAN

Global and US Drug Devt Ctr

- Immunology platform - Respiratory diseases - RA - CNS

European Drug Devt Ctr

Asian Drug Devt Ctr

- Oncology, - Infectious Diseases - Neurodegenerative Diseases, (Parkinson & Alzheimer),

• ~6500 scientists & technicians worldwide

5

Drug Innovation & Approval in France

5 km

CDG Airport

ESSONNE

VAL DE MARNE

HAUTS DE SEINE

PARIS

SEINE ST DENIS

Romainville

Vitry-Alfortville

Croix de Berny

Evry

• Paris Research Centre• European Drug Devt Centre

• ~2800 scientists & technicians

6

New drug discovery technologies

Candidate Identification

LeadIdentification

TargetSelection

PreclinicalCandidate

Identification PhI / IIaPhIIb PhIII Regulatory

Review

Functional Genomics Technologies DNA chipsProteomics, cellular & animal models..

Lead Identification Technologies MedChem, ChemBiol, Structural Genomics and Biology…. Technologies for Exploratory

Development eADMET, TGX, PGX, Biomarkers….

Technologies for Global

Rapid submissions e-submissions…..

Integrated Data and Knowledge Management

7

Integration of Genomics Technologies &Disease Biology Platforms

GenomicsTechnologyPlatforms

Aventis Genomics Centers

DiseaseBiology

Platforms

Metabolism OncologyCNS / ND

Cardiovascular Rheumatoid

Arthritis Osteoarthritis - DJD Respiratory Diseases Anti-

Infectives Immunology

platform

Exte

rnal C

ollab

ora

tion

s &

N

etw

ork

s

Exte

rnal C

ollab

ora

tion

s &

N

etw

ork

s

Targets relevant to disease

8

Key Challenges

•The post-human genome sequence race • functional genomics• proteomics• protein structure prediction • re-thinking chemical approaches• re-thinking clinical development

•Continuous integration of technologies (alliances and partnering), information and knowledge (knowledge networks)

•Availability of skilled work force (right skill-set and mind-set)

9

In partnership with the European Commission: 12 Marie Curie Industry

Host Fellowships for a 2 year period.

Post-doc Opportunities in Aventis Pharma, France

•Parkinson’s Disease Gene Targets (3 positions)

•Molecular Modeling and High Throughput Medicinal Chemistry (3 positions)

•From Protein-Protein Interactions (yeast 2H) to Lead Discovery Process (3positions)

•Cardiovascular Gene Therapy (1 position)

•Adenoviral Vector-based system for Functional Genomics (1 position)

•Bio-Informatics in Toxicogenomics (1 position)

Immediate Starting Date

10

In partnership with the European Commission

Post-doc Opportunities in Aventis Pharma, France

The position are open to members of the E.C. or resident of associated countries for more than 5 years.

The age limit at the time of selection is 35 years old. Austria, Belgium, Bulgaria, Czech republic, Denmark, Estonia, Finland, Germany

Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Liechtenstein

Lithuania, Luxembourg, Netherlands, Norway, Poland, Portugal, Republic of Cyprus, Romania

Slovakia, Slovenia, Sweden, Spain, United Kingdom

However French citizens are ineligible as well as those who have been resident in France for more than 12 out of the last 24 months.

11

Coming soon

9 post-doctoral positions

Post-doc Opportunities in Aventis Pharma, France

•Kinases in Oncology and Neurodegenerative diseases•Gene Transfer in Angiogenesis

•Genomic Studies for the glial-neuronal interactions

•Statistics for Pharmacogenetics

12

Post-doc Opportunities in Aventis Pharma, France

• 250 KF/year (38KEuros/year)• Social security included• 26 + 12 days holiday

• Project Team • Networking• Publications/patents

• Confidentiality

13

Come and join us on the Aventis stand to learn more about our post-doctoral opportunities !

edith.heuillet@aventis.com